Module 2: Acalabrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MSCE
8:16
Chronic Lymphocytic Leukemia
Module 2: Acalabrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MSCE
Chronic Lymphocytic Leukemia Similar Videos
Similar Videos
-
Module 4: Emerging BTK Inhibitors_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE
12:02
-
Module 3: Zanubrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, Anthony Mato, MD, MSCE
7:59
-
Recently presented data and optimal therapeutic approaches in relapsed/refractory CLL_Jennifer Brown, MD, PhD; #BeyondASCO
13:52
